this page only  
Join BIO   |   Member Directory   |    Contact BIO    
Biotechnology Industry Organization

Home
About BIO
Conferences & Events
Past BIO Events
Industry Calendar
State/Int'l Calendar
Members.BIO.org
BIO News Online
BIO Bulletins
Suggestion Box
Membership Directory
BIO Videos
News & Media
BIO Blogs & Podcasts
National Issues
Health
Food & Agriculture
Industrial & Environmental
Bioethics
Intellectual Property
Regulatory
• Tax & Financial
State & Local Issues
State by State Initiatives
Letters, Testimony & Comments
Speeches & Publications
Industry At-a-Glance
Business & Finance
BIO News


Saturday, November 21, 2009

Net Operating Losses

overviewlegislative issues
accounting issuesnet operating losses
archivesbir
collaborationsstock options
fundingtax issues

Economic Stimulus Options to Promote Innovation and Job Creation by U.S. ResearchIntensive Emerging Companies. One Time Refund of NOLs in Lieu of Other Tax Benefits to Sustain Critical R&D During Financial Distress.

Description: Allow companies to temporarily elect to receive a refund of their accumulated net operating losses (NOLs) at a discounted rate in lieu of claiming qualified research expenses, as defined by Code §41(b), for Tax Year 2008. The proposal would have the following features:

  • Election to receive a refund of accrued NOLs at a discounted rate (i.e., 35% corporate tax rate minus a discount percentage).
  • Refunds must be reinvested in investments that would qualify as U.S.- based research expenses under Code §41(b).
  • Company would permanently forgo the opportunity to claim all NOLs involved in the computation of the refund.
  • Applies only to loss companies in Tax Year 2008.
  • Limited to small companies.
  • Refund capped at a per company dollar amount

Example: Assuming a discount percentage of 15%, a small biotech/hightech/ clean-tech company with $100M in accumulated NOLs could elect to claim a refund of $20M on their 2008 tax return ($100M x (35% -] 15%) = $20M). The $20M refund could only be used to pay for U.S.– based research activities. The company would forgo the ability to carry forward the remaining $80M in NOLs for future tax years.

Rationale: Many of America's most-promising companies in the areas of science and technology are struggling to raise the necessary research funding to survive the current economic slowdown and may disappear if economic conditions do not improve in the very near future. In order to save the high-paying, research-intensive jobs of America's innovation economy, Congress should allow companies to accelerate the utilization of their tax assets. Companies struggling to conduct capital-intensive R&D and meet payroll during the economic downturn will forgo a larger tax benefit in the future to claim a smaller tax benefit today. The proposal has minimal revenue impact since companies are only claiming accumulated NOLs at a substantial discount in return for forgoing the ability to claim remaining NOLs for future tax years.


contact us | terms of use | privacy policy
© 2009 | Biotechnology Industry Organization | 1201 Maryland Ave., SW, Ste. 900 | Washington, D.C. 20024